Portal de investigación
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perez-Gisbert, J
- Bosca-Watts, MM
- Lopez-Garcia, A
- Garcia-Sanchez, V
- Hinojosa, E
- Marquez, L
- Garcia-Lopez, S
- Aceituno, M
- Calafat, M
- Guardiola, J
- Belloc, B
- Ber, Y
- Bujanda, L
- Rodriguez-Gutierrez, C
- Barrio, J
- Cabriada, JL
- Rivero, M
- Camargo, R
- van Domselaar, M
- Villoria, A
- Schuterman, HS
- Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Grupos
Abstract
Background Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors of remission to ADA. Methods This cohort study used data from the ENEIDA registry. Clinical response, clinical remission, endoscopic remission, adverse events (AE), colectomy, and hospitalisations were evaluated; baseline characteristics and biological parameters were compared to determine predictors of response. Results We included 263 patients (87 naive and 176 previously exposed to anti-tumour necrosis factor alpha, TNF). After 12 weeks, clinical response, clinical remission, and endoscopic remission rates were 51, 26, and 14 %, respectively. The naive group demonstrated better response to treatment than the anti-TNF-exposed group at short-term. Clinical and endoscopic remission within 1 year of treatment was better in the naive group (65 vs. 49 and 50 vs. 35 %, respectively). The rates of AE, dose-escalation, hospitalisations, and colectomy during the first year were higher in anti-TNF-exposed patients (40, 43, and 27 % vs. 26, 21, and 11 %, respectively). Patients with primary failure and intolerance to the first anti-TNF and severe disease were associated with worse clinical response. Primary non-response to prior anti-TNF treatment and severe disease were predictive of poorer clinical remission. Low levels of C-reactive protein (CRP) and faecal calprotectin (FC) at baseline were predictors of clinical remission. Conclusions In clinical practice, ADA was effective in UC, especially in anti-TNF naive patients. FC and CRP could be predictors of treatment effectiveness.
Datos de la publicación
- ISSN/ISSNe:
- 0944-1174, 1435-5922
- Tipo:
- Article
- Páginas:
- 788-799
- PubMed:
- 27722996
- Factor de Impacto:
- 2,322 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK
Citas Recibidas en Web of Science: 57
Documentos
- No hay documentos
Filiaciones
Keywords
- Adalimumab; Ulcerative colitis; Treatment
Campos de Estudio
Cita
IBORRA M,Perez J,Bosca MM,Lopez A,Garcia V,LOPEZ A,Hinojosa E,Marquez L,Garcia S,CHAPARRO M,Aceituno M,Calafat M,Guardiola J,Belloc B,Ber Y,Bujanda L,BELTRAN B,Rodriguez C,Barrio J,Cabriada JL,Rivero M,Camargo R,van M,Villoria A,Schuterman HS,HERVAS D,NOS P,Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU). Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients. J Gastroenterol. 2017. 52. (7):p. 788-799. IF:5,561. (1).